Skip to main content

Advertisement

Fig. 3 | BMC Musculoskeletal Disorders

Fig. 3

From: Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial

Fig. 3

a and b Anti pneumococcal and anti tetanus antibody status at baseline and at 24 weeks. a Anti pneumococcal antibody titres at baseline and 24 weeks. Leflunomide shows significant difference of anti pneumococcal antibodies at 24 weeks compared to baseline (P < 0.05). Rituximab shows significant difference of anti pneumococcal antibodies at 24 weeks compared to baseline (P < 0.05) Anti pneumococcal anti body - Minimum accepted level - 20 U/ml. b Anti-tetanus antibody titres at baseline and 24 weeks. Leflunomide shows no significant difference of anti-tetanus antibodies at 24 weeks compared to baseline (P > 0.05). Rituximab shows no significant difference of anti tetanus antibodies at 24 weeks compared to baseline (P > 0.05). Data Analysed using non parametric Wilcoxan Rank Sum test as paired samples. Anti tetanus antibody <0.01 IU/ml Non protective, 0.01– 0.09 IU/ml No reliable protection

Back to article page